









市場行情
/
股票
/
nasdaq-nuvb
/

Nuvation Bio Inc

NUVB

8.965USD

+0.025+0.28%

收盤 12/31, 16:00（美東）報價延遲15分鐘

3.07B總市值

虧損本益比TTM



Nuvation Bio Inc

8.965

+0.025+0.28%

概覽公司財務分析

概覽

公司

財務

分析

關於 Nuvation Bio Inc 公司

Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Nuvation Bio Inc簡介



公司代碼NUVB

公司名稱Nuvation Bio Inc

上市日期Jul 01, 2020

CEOHung (David T)

員工數量220

證券類型Ordinary Share

年結日Jul 01

公司地址1500 Broadway

城市NEW YORK

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United States of America

郵編10036

電話13322086102

網址https://www.nuvationbio.com/

公司代碼NUVB

上市日期Jul 01, 2020

CEOHung (David T)

Nuvation Bio Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. David T. Hung, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

60.28M

+0.84%

Mr. Kim D. Blickenstaff

Independent Director

172.19K

Dr. Robert Mashal, M.D.

Independent Director

100.00K

Ms. Colleen Sjogren

Chief Commercial Officer

78.00K

+178.57%

Ms. Kerry A. Wentworth

Chief Regulatory Officer

50.00K

Mr. Moses Makunje, CPA

Principal Accounting Officer, Vice President - Finance

10.61K

Ms. Stacy Markel

Chief People Officer

10.00K

Mr. Philippe Sauvage

Chief Financial Officer and Principal Financial Officer

7.30K

Mr. Robert B. (Rob) Bazemore, Jr.

Lead Independent Director

5.00K

Mr. Joe Rayne

Investor Relations

名稱

名稱/職務

職務

持股

持股變動

Dr. David T. Hung, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

60.28M

+0.84%

Mr. Kim D. Blickenstaff

Independent Director

172.19K

Dr. Robert Mashal, M.D.

Independent Director

100.00K

Ms. Colleen Sjogren

Chief Commercial Officer

78.00K

+178.57%

Ms. Kerry A. Wentworth

Chief Regulatory Officer

50.00K

Mr. Moses Makunje, CPA

Principal Accounting Officer, Vice President - Finance

10.61K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Hung (David T)

17.63%

Fidelity Management & Research Company LLC

14.64%

Decheng Capital LLC

7.59%

BlackRock Institutional Trust Company, N.A.

5.84%

The Vanguard Group, Inc.

4.50%

其他

49.78%

持股股東

佔比

Hung (David T)

17.63%

Fidelity Management & Research Company LLC

14.64%

Decheng Capital LLC

7.59%

BlackRock Institutional Trust Company, N.A.

5.84%

The Vanguard Group, Inc.

4.50%

其他

49.78%

股東類型

持股股東

佔比

Investment Advisor

31.19%

Individual Investor

19.21%

Hedge Fund

11.09%

Venture Capital

10.58%

Investment Advisor/Hedge Fund

10.37%

Research Firm

1.68%

Private Equity

0.42%

Bank and Trust

0.23%

Pension Fund

0.20%

其他

15.03%

機構持股



更新時間: 1 小時前

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

368

224.86M

65.78%

-37.90M

2025Q3

355

228.75M

66.72%

-24.74M

2025Q2

346

279.19M

82.03%

-27.71M

2025Q1

346

276.31M

81.30%

-31.14M

2024Q4

336

290.52M

86.58%

+4.56M

2024Q3

324

278.55M

83.07%

+36.83M

2024Q2

323

221.78M

89.68%

-2.09M

2024Q1

305

194.38M

89.06%

-41.04M

2023Q4

290

194.02M

89.00%

-35.90M

2023Q3

285

196.95M

90.37%

-25.21M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Hung (David T)

60.28M

17.61%

+500.00K

+0.84%

Jun 16, 2025

Fidelity Management & Research Company LLC

50.47M

14.75%

+440.09K

+0.88%

Jun 30, 2025

Decheng Capital LLC

25.95M

7.58%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

20.99M

6.13%

+5.12M

+32.27%

Jun 30, 2025

The Vanguard Group, Inc.

15.84M

4.63%

+505.23K

+3.29%

Jun 30, 2025

Laurion Capital Management LP

10.24M

2.99%

+369.63K

+3.74%

Jun 30, 2025

Omega Fund Management, LLC

11.04M

3.23%

-2.03M

-15.53%

Jun 30, 2025

State Street Investment Management (US)

5.56M

1.62%

+702.97K

+14.48%

Jun 30, 2025

Geode Capital Management, L.L.C.

5.99M

1.75%

+864.19K

+16.84%

Jun 30, 2025

Millennium Management LLC

5.38M

1.57%

+1.61M

+42.56%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

State Street SPDR S&P Pharmaceuticals ETF

2.51%

Virtus LifeSci Biotech Clinical Trials ETF

1.95%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.79%

Tema Oncology ETF

1.66%

ALPS Medical Breakthroughs ETF

0.74%

iShares U.S. Pharmaceuticals ETF

0.46%

iShares Micro-Cap ETF

0.25%

iShares Health Innovation Active ETF

0.24%

Avantis US Small Cap Equity ETF

0.16%

iShares Biotechnology ETF

0.11%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.51%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.95%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.79%

Tema Oncology ETF

佔比1.66%

ALPS Medical Breakthroughs ETF

佔比0.74%

iShares U.S. Pharmaceuticals ETF

佔比0.46%

iShares Micro-Cap ETF

佔比0.25%

iShares Health Innovation Active ETF

佔比0.24%

Avantis US Small Cap Equity ETF

佔比0.16%

iShares Biotechnology ETF

佔比0.11%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Nuvation Bio Inc的前五大股東是誰？



Nuvation Bio Inc的前五大股東如下：
Hung (David T)
持有股份：60.28M
佔總股份比例：17.61%。
Fidelity Management & Research Company LLC
持有股份：50.47M
佔總股份比例：14.75%。
Decheng Capital LLC
持有股份：25.95M
佔總股份比例：7.58%。
BlackRock Institutional Trust Company, N.A.
持有股份：20.99M
佔總股份比例：6.13%。
The Vanguard Group, Inc.
持有股份：15.84M
佔總股份比例：4.63%。